hotspot -WSS

hotspot

author：Wikipedia 2025-10-02 18:48:33 - browse：415

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Life sciences investors close nearly $6 billion in new funds

WSS

Boston competes with Raleigh

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Humana’s losses in Medicare Advantage tank its stock

Vertex non

Life sciences investors close nearly $6 billion in new funds

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Moonlake's readout produced a cash windfall. Risks remain

The Affordable Care Act has saved billions in health care costs

Cancer drug shortages should be causing more outrage

Life sciences investors close nearly $6 billion in new funds

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Humans aren't the only ones with an imagination. Rats have it too

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

FTC sues over Novant Health acquisition of two N.C. hospitals

The cancer drug shortage isn’t new — and neither are the solutions

Coloradans with cystic fibrosis could lose access to Trikafta

focus

Sarepta Duchenne therapy fails to meet primary endpoint in trial

What is microchimerism and how does it affect maternal health?

Gene therapy’s promise and the high cost of hope

Lung cancer screening guidelines updated for cigarette smokers

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

DeepMind touts AlphaFold's new skills as protein folding AI models face off

explore

leisure time

hotspot

entertainment